Call for papers - Advancing immunotherapy against gynecological cancer

Guest Editor

Peixin Dong, MD, PhD, Hokkaido University, Japan

Submission Status: Open | Submission Deadline: 11 April 2025

BMC Women’s Health is pleased to welcome submissions to the Collection Advancing immunotherapy against gynecological cancer.

This Collection seeks to showcase research that explores immune checkpoint inhibitors in ovarian cancer, the tumor microenvironment in cervical cancer, personalized immunotherapeutic strategies, and immune-related adverse events in gynecological cancer patients. By advancing our understanding of immunotherapy in gynecological cancers, this Collection aims to drive the development of novel, effective treatment approaches to improve outcomes for women with gynecological malignancies.

New Content Item This Collection supports and amplifies research related to SDG 3: Good Health & Well-Being and SDG 5: Gender Equality.

Submit to Collection

Meet the Guest Editor

Back to top

Peixin Dong, MD, PhD, Hokkaido University, Japan

Peixin Dong, MD, PhD, is a Principal Investigator in the Department of Obstetrics and Gynecology at Hokkaido University, Japan. His research focuses on understanding the molecular mechanisms driving gynecological cancer metastasis and developing novel anti-cancer therapies. With over 70 published papers, his expertise spans non-coding RNA, cancer biology, bioinformatics, and biomarker discovery. Dr Dong has identified key molecular pathways involved in cancer progression and drug resistance, particularly in endometrial and ovarian cancers. He has received several awards for his work and actively participates in various editorial roles and research funding initiatives.

About the Collection

BMC Women’s Health is pleased to welcome submissions to the Collection Advancing immunotherapy against gynecological cancer.

Gynecological cancer is a kind of tumor identified in the female reproductive organs, including ovarian, cervical, uterine, vaginal, and vulvar cancers, and significantly challenges the health of women worldwide. Immunotherapy represents a promising avenue for the treatment of gynecological cancer by dynamically altering the body's immune system to target and destroy cancer cells in pathways distinct from traditional treatment approaches such as radiotherapy, chemotherapy, surgery, or a combination of these methods. Understanding the interplay between the immune system and various gynecological cancers is crucial for advancing novel therapeutic approaches and improving patient outcomes.

Interventional anti-tumor based immunity has made considerable progress by checkpoint blockade, vaccination and adaptive cellular therapy in certain gynecological cancers. Ongoing research has elucidated the complex tumor microenvironment and immune evasion mechanisms, providing insights into potential targets for immunotherapy. Identification of the nuances of immune-related adverse events and patient selection criteria is essential for optimizing the immunotherapy in gynecological cancers. Further exploration of biomarkers and refined therapy combinations may lead to the development and leverage of personalized immunotherapeutic strategies of gynecological cancers.

Topics welcome for submission to the Collection may include but are not limited to:

Novel checkpoint inhibitor-based immunotherapy in gynecological cancer
Research and clinical strategies targeting the tumor microenvironment in gynecological cancer
Personalized immunotherapeutic strategies for different types of gynecological cancers
Immune-related adverse events in gynecological cancer patients
Predictive biomarkers for improving checkpoint blockades

This Collection supports and amplifies research related to SDG 3: Good Health & Well-Being and SDG 5: Gender Equality.

There are currently no articles in this collection.

Submission Guidelines

Back to top

This Collection welcomes submission of original Research Articles. Should you wish to submit a different article type, please read our submission guidelines to confirm that type is accepted by the journal. Articles for this Collection should be submitted via our submission system, Snapp. During the submission process you will be asked whether you are submitting to a Collection, please select "Advancing immunotherapy against gynecological cancer" from the dropdown menu.

Articles will undergo the journal’s standard peer-review process and are subject to all of the journal’s standard policies. Articles will be added to the Collection as they are published.

The Editors have no competing interests with the submissions which they handle through the peer review process. The peer review of any submissions for which the Editors have competing interests is handled by another Editorial Board Member who has no competing interests.